Organon's DEI Employment Practices: What the Company's Own Documents Show — and What They Mean for Employees

Published August 27, 2026 · Last updated August 27, 2026 · By Fett Law — Michigan Employment Discrimination Attorneys

Organon & Co. published a goal to reach "balanced gender representation through all levels of the company globally by 2030," piloted a leadership program limited to "promising female employees," and built recruiting partnerships intended to "build diverse talent pools" — in its own ESG reports and proxy statements from 2021 through April 2026. Organon LLC holds U.S. Department of Veterans Affairs pharmaceutical contracts and a Defense Health Agency award. Practices of these kinds were the basis of two False Claims Act settlements with the U.S. Department of Justice: IBM's $17,077,043 in April 2026 and Deloitte's $21,500,000 effective August 21, 2026, in which the whistleblower was paid $4,300,000. Both resolved allegations only, with no determination of liability, and Deloitte denies the conduct.

Key facts

Did Organon set gender representation goals?

The goal is stated in Organon's own words, and it is not framed as aspiration alone — the company describes the mechanism it intends to use to reach it:

"We aim to achieve balanced gender representation through all levels of the company globally by 2030." Organon FY2021 ESG Report (published June 2022), "Diversity, equity, inclusion, and belonging" section. The same sentence appears in the 2022 ESG Report at page 12.

"To reach this goal, we will maintain our current global gender balance while increasing the number of women in mid- and senior leadership roles." Organon FY2021 ESG Report (published June 2022), "Diversity, equity, inclusion, and belonging" section.

Organon then reported movement against the goal by year:

"Our female representation in roles at director-level and above increased from 43.45% in 2021 to 46.70% in 2022." Organon 2022 ESG Report, page 12 (published June 2023).

By the 2024 ESG Executive Summary, the figure was "47% female representation in roles at director-level and above." The goal itself carried forward into the proxy statements: the 2024 proxy states at page 17, "We aim to achieve balanced gender representation through all levels of the company globally by 2030, and achieve pay equity," and the proxy filed in April 2026 states at page 18, "We strive to achieve balanced gender representation through all levels of the Company globally by 2030, and achieve pay equity." The verb softened from "aim" to "aspire" to "strive"; the target and the 2030 date did not change.

What this meant in practice. A representation target attached to "all levels of the company" and tracked by year is a measurement applied to promotion and hiring outcomes across the organization. Whether such a goal ever changed a particular decision about a particular person is a factual question that depends on internal records — not something a public report answers. That is precisely the question an employee who was passed over for a director-level promotion between 2021 and 2026 would want answered.

Organon set a parallel numeric goal outside employment, in procurement: the FY2021 ESG Report committed to a "25% increase of our addressable spend with diverse suppliers by 2025, from a 2021 baseline," and the 2022 ESG Report reported that Organon "increased diverse spend by 48% over 2021 actuals, achieving this goal in 2022."

Source: Organon FY2021 ESG Report · Organon 2022 ESG Report · 2024 Proxy Statement.

Did Organon run a program restricted by sex?

"In 2021, we piloted a Women's Leadership Program for promising female employees in our Commercial and Manufacturing divisions. We are now expanding eligibility to other functional areas." Organon FY2021 ESG Report, page 36, "Diversity, equity, inclusion, and belonging" (published June 2022).

What this meant in practice. A leadership-development program is a career accelerator: it supplies visibility to senior decision-makers, structured coaching, and a signal that the participant is on a promotion track. Where eligibility for that accelerator turns on sex, employees of the other sex in the same divisions — Commercial and Manufacturing, in Organon's description — were not eligible for it, however strong their performance. In the Deloitte matter, the United States described two programs, Springboard and Compass, "where eligibility to participate was limited on the basis of race and sex," as part of the conduct it resolved.

The program disappears from Organon's disclosure after the FY2021 report: it is not named in the 2022 ESG Report, and it does not appear in the 2024 ESG Executive Summary. Organon's live careers site describes ten employee resource groups and states that they are "open to all employees," and the company's FY2025 Form 10-K likewise describes the ten ERGs as "each of which is open to all" employees — language that did not appear in the FY2021 Form 10-K.

Source: Organon FY2021 ESG Report, page 36.

Did Organon use race- or sex-conscious hiring and sourcing?

The company's stated approach is pipeline-and-outreach:

"For example, we have established partnerships with various diversity-focused organizations and associations, including Women of Color in Pharma, myGwork, and Diversity:IN, to help us build diverse talent pools." Organon FY2021 ESG Report, page 36 (published June 2022).

"We are building a Global Talent Sourcing team to identify and engage with diverse talent in the marketplace." Organon FY2021 ESG Report, page 36 (published June 2022).

"That means we go beyond gender to advance equity among historically underrepresented minority groups as defined by their geographic and cultural context." Organon FY2021 ESG Report, page 36 (published June 2022).

Why the distinction matters. Broad outreach that widens the pool of people who learn about an opening is lawful, and courts have consistently treated it that way. The legal question arises when a protected characteristic moves from who hears about a job to who gets it — when a slate must contain particular demographics, when a candidate list is annotated by race or sex, or when a hiring decision is measured against a representation number. Organon's published documents describe the first and not the second. What they cannot show is how the sourcing operated inside the company, or whether the 2030 representation goal described above reached selection decisions. That is what internal recruiting records, requisition files, and hiring-manager communications would show.

Source: Organon FY2021 ESG Report, page 36.

What Organon's documents do not show

This section exists because the honest answer matters. In both the IBM and Deloitte settlements, compensation linked to demographic targets was central to what the government described. Organon's record is different, and it should not be described as if it were the same.

What Organon did disclose:

"Although we have ESG-related metrics embedded in our Company Scorecard, which has an impact on executive compensation, we do not currently include any access-related metrics on the scorecard." Organon 2022 ESG Report, page 29 (published June 2023).

"The Talent Committee plays a role in the selection and oversight of the specific metrics from the ESG strategy that are included in the Company Scorecard, which affect annual incentive payouts." Organon 2022 ESG Report, page 12 (published June 2023). The same sentence appears in the 2024 Proxy Statement at page 18.

From the proxy filed in 2025 onward, Organon named the human-capital scorecard component explicitly: "the employee engagement aspect of our ESG strategy was also embedded into the 2024 Company Scorecard, which impacted annual incentive payouts," and the same formulation for 2025 in the April 2026 proxy. A full-text search of Organon's SEC filings returns no instance of the phrase "diversity metrics," "diverse slate," or "diverse candidate."

Whether any diversity or representation measure sat inside the ESG component of the FY2021–FY2023 scorecards is not answered by the public record. Compensation-committee materials, scorecard worksheets, and individual performance objectives are internal documents. An Organon manager or executive who saw those materials would know something the filings do not disclose.

How Organon's DEI program changed, 2021–2026

Where Organon's DEI reports went

This is the practical point for anyone who worked at Organon during those years: the documents that describe the programs are the FY2021 and 2022 ESG Reports, and they are no longer where a reader would look for them. Both are linked directly in the Sources section below.

Two further changes are visible in the current record. The full annual ESG report format appears to have been discontinued after 2023, replaced by a four-page executive summary. And the corporate diversity page has been renamed: the page that carries the URL slug diversity-equity-inclusion now renders under the heading "Inclusion, innovation, and belonging," and the term "DEI" does not appear on it. The URL is the fossil of the old title.

What was not rolled back matters just as much. The 2030 balanced-gender-representation goal survives in the proxy statements filed in April 2025 and April 2026 — after Executive Order 14173 — and the board diversity matrix is retained through the 2026 proxy. Organon's careers site still publishes a page headed "Diversity, equity & inclusion." The rollback here is real but partial and largely terminological.

Why these practices matter legally

Title VII applies in every direction. The statute, 42 U.S.C. § 2000e-2, makes it unlawful to discriminate "because of such individual's race, color, religion, sex, or national origin" — with no carve-out for majority groups. In Muldrow v. City of St. Louis (2024), the Supreme Court held that a plaintiff challenging a discriminatory job transfer need show only some harm to a term or condition of employment, not a "significant" one. In Ames v. Ohio Department of Youth Services (2025), the Court held unanimously that majority-group plaintiffs face no heightened evidentiary standard. Together, those decisions lowered two barriers that used to stop cases like these early.

Section 1981 reaches race in contracts. 42 U.S.C. § 1981 guarantees the same right to make and enforce contracts, including employment contracts, regardless of race. It has a four-year limitations period, requires no administrative charge first, and — unlike Title VII — carries no cap on compensatory or punitive damages.

The False Claims Act route for federal contractors. On April 10, 2026, the U.S. Department of Justice announced that IBM would pay $17,077,043 to resolve False Claims Act allegations that it failed to comply with anti-discrimination requirements in its federal contracts — the first settlement under the DOJ's Civil Rights Fraud Initiative. In August 2026 the government resolved a second, larger matter: under a settlement agreement effective August 21, 2026, five Deloitte entities agreed to pay $21,500,000, of which $9,995,000 was restitution, covering conduct from January 1, 2017 through the settlement date. The certification hook is specific — Title VII as incorporated into federal contracts and FAR clause 52.222-26 — and the government's theory reached not only what Deloitte certified to its contracting agencies but what it "publicly represented" about its compliance. The agreement adds a second and independent theory: that Deloitte "allocated costs to its federal government contracts relating to these practices and sought payment and reimbursement under its federal government contracts for such costs." The whistleblower was paid $4,300,000. Both settlements resolved allegations only, with no determination of liability, and Deloitte denies the conduct.

Organon's parallel fact is its contractor status. Organon LLC holds Department of Veterans Affairs Federal Supply Schedule pharmaceutical contracts — federal contracting records show awards running from the 2021 spin-off through at least July 2027 — and a 2023 Defense Health Agency award. Organon's own careers-site equal employment opportunity policy statement, signed in April 2025, invokes Section 503 of the Rehabilitation Act and the Vietnam Era Veterans' Readjustment Assistance Act, the two contractor-specific authorities. Whether any certification Organon made was inaccurate is not established by anything public, and nothing here asserts that it was.

A government settlement is not the end of it. A Justice Department settlement resolves only the United States' claims. The Deloitte agreement expressly reserves any pending or future charges filed with the Equal Employment Opportunity Commission — including charges "which may allege the same covered conduct described in this Agreement" (¶ 5(d)) — reserves "[a]ny liability of individuals" (¶ 5(g)), and reserves administrative liability and suspension and debarment (¶ 5(c)). Remaining claims were dismissed without prejudice to the United States (¶ 12).

For the complete framework — the four illegal DEI practice categories and when you can sue — see our guide, Is DEI Illegal? 4 Illegal DEI Practices & When You Can Sue.

Were you affected by these practices at Organon?

The documented practices point to specific situations. You may want a confidential assessment if, at Organon & Co. or Organon LLC:

• You were passed over for a director-level or senior role between 2021 and 2026, in a period when the company was publicly reporting year-over-year female representation at director level and above against a 2030 target.
• You were not eligible for the Women's Leadership Program because of your sex — particularly in the Commercial or Manufacturing divisions, where it was piloted, or in a function it was later expanded into.
• You applied and were screened out and have reason to believe demographic considerations shaped who advanced.
• You are a manager, recruiter, HR professional, or executive who saw how the representation goal was operationalized — scorecards, requisition instructions, slate reviews, promotion calibration sessions, or compensation-committee materials. That is non-public, first-hand knowledge, and it is exactly what the False Claims Act rewards.

A federal settlement is not a substitute for your own claim: when the Justice Department resolved the Deloitte matter, it expressly preserved the EEOC's right to pursue charges alleging the very same conduct, and preserved individual liability. Nothing about that settlement compensated a single employee or applicant.

Consultations are free and confidential, in person or by Zoom, anywhere in the country, and representation is on contingency — no fees unless the firm wins. Because Organon LLC is a federal contractor, an employee with insider knowledge may also be able to bring a False Claims Act claim on the government's behalf and share in any recovery; qui tam complaints are filed under seal, so the employer is not told at the outset. Both Title VII and the False Claims Act prohibit retaliation against people who assert their rights or report misconduct.

If any of these fits, it costs nothing to find out where you stand — meet our DEI discrimination lawyers, or start below.

What could a claim against Organon be worth?

False Claims Act whistleblower awards

Under 31 U.S.C. § 3730(d), a qui tam relator receives 15–25% of the government's recovery when the Department of Justice intervenes, and 25–30% when the relator proceeds without intervention. The Deloitte settlement supplies a paid benchmark rather than a projection: the relator received $4,300,000 — exactly 20% of a $21,500,000 recovery. That settlement also shows why False Claims Act exposure outruns the money actually lost. Of the $21.5 million, $9,995,000 was restitution — roughly the government's single damages — so the resolution came to about 2.15 times the actual loss, because FCA recoveries are built on multiplied damages plus per-claim penalties. As a second illustration, arithmetic alone: an intervened case resolving at IBM's $17,077,043 would pay a relator roughly $2.6–$4.3 million. A contractor with a larger federal book or a longer conduct period could produce a materially larger number. A relator's expenses, attorney's fees and costs are resolved separately from the relator's share.

Damages in an individual discrimination case

Back pay and front pay are uncapped under Title VII. Compensatory and punitive damages are capped by employer size — $50,000 for employers with 15–100 employees, $100,000 for 101–200, $200,000 for 201–500, and $300,000 for employers with more than 500. Organon, with roughly 10,000 employees worldwide, sits at the $300,000 cap. But 42 U.S.C. § 1981 has no damages cap at all, which is why race claims are often pleaded under it, and many state statutes have no cap either — New Jersey's Law Against Discrimination, which covers Organon's Jersey City headquarters, allows uncapped compensatory and punitive damages. Prevailing plaintiffs generally recover attorney's fees on top of damages.

For scale, from this firm's own prior results: a $10.5 million race and age discrimination class action against Ford Motor Company; a $2 million disability hostile work environment result; a $1.6 million racial harassment result; a $1.1 million race and gender discrimination judgment against the Michigan State Police. Prior results do not guarantee a similar outcome.

Class action potential

A single policy applied to many people is the raw material of a class action. A leadership program with sex-based eligibility, or a representation target applied across "all levels of the company," is by definition one policy touching a large group — which is what makes classwide treatment possible where the facts support it. No class action against Organon & Co. arising from these practices is known to be pending. For historical scale in employment discrimination class litigation: Coca-Cola settled for $192.5 million in 2000, Texaco for $176.1 million in 1996, and Novartis for $175 million in 2010.

Every case depends on its own facts; these figures show the range the law makes possible, not a prediction. The way to find out what your own situation supports is to start a confidential intake.

Sources